Rezolute Reports Wider Net Loss and Increased Burn, Pivots Key Trial Design After sunRIZE Failure

summarizeSummary

Rezolute, Inc. reported a significantly wider net loss and increased cash burn for the six months ended December 31, 2025, following the failure of its sunRIZE Phase 3 trial, but announced a de-risked Phase 3 design for its upLIFT tumor HI study.

check_boxKey Events

• Wider Net Loss Reported

  The company reported a net loss of $40.9 million for the six months ended December 31, 2025, compared to $31.1 million in the prior year period.

• Increased Cash Burn

  Net cash used in operating activities rose to $37.8 million for the six months ended December 31, 2025, up from $29.7 million in the same period last year.

• upLIFT Trial Design De-risked

  The FDA agreed to a single-arm, open-label Phase 3 design for the upLIFT study in tumor hyperinsulinism, removing the placebo control and potentially accelerating development.

• Liquidity Runway Confirmed

  Management projects current cash and marketable securities totaling $132.9 million will fund operations for at least 12 months from the filing date.

auto_awesomeAnalysis

The Q2 FY26 10-Q confirms a substantial widening of net loss and increased cash burn, reflecting the financial impact of the sunRIZE trial failure. While the sunRIZE setback was previously disclosed, the detailed financials highlight the company's ongoing need for capital. A key positive development is the FDA's agreement to a single-arm, open-label Phase 3 design for the upLIFT study in tumor hyperinsulinism, which significantly de-risks this crucial remaining clinical asset and could accelerate its path to market. The company also maintains a cash runway of at least 12 months, providing near-term stability despite the operational losses. Investors will be closely watching the progress of the upLIFT trial and the upcoming FDA meeting regarding the sunRIZE data.